Drug profile · INN
loteprednol etabonate
EYSUVIS
loteprednol etabonate (EYSUVIS) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — loteprednol etabonate
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
loteprednol etabonate (EYSUVIS) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is loteprednol etabonate?
loteprednol etabonate (EYSUVIS) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for loteprednol etabonate?
EYSUVIS is a marketed brand name for loteprednol etabonate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of loteprednol etabonate?
loteprednol etabonate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.